Johns Hopkins Cancer Center | Strategic Alliance Partners

Latest from Johns Hopkins Cancer Center

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 07, 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Meyer Characterizes Current Approaches to Diagnosing, Managing, and Studying Cardiac Angiosarcoma

January 10, 2022

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.

Chemotherapy-Free Strategies Chart a New Course for Ph-Positive ALL

August 24, 2021

A new era for patients with newly diagnosed Philadelphia chromosomepositive acute lymphoblastic leukemia may be on the horizon as investigative efforts aimed away from chemotherapy-based regimens prove efficacious.

Novel Compound Looks to Shake Up mCRPC Treatment Landscape

August 19, 2021

The discovery of an agent with a unique mechanism of action led investigators to examine sabizabulin, an oral therapy that binds to the colchicine binding site on the microtubule to crosslink α and β tubulin and inhibits microtubule polymerization.

Neoadjuvant Nivolumab/Chemo Improves pCR in Resectable NSCLC

April 10, 2021

Neoadjuvant treatment with nivolumab combined with chemotherapy led to a significant improvement in pathologic complete response compared with chemotherapy alone in patients with resectable non–small cell lung cancer.

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 05, 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.